Diagnostic Assays for Hematological Malignancies
Leukemia Genetic Testing
Typical chromosomal rearrangements like translocations are often associated with a certain type of hematological cancer. For example, the well known Philadelphia chromosome, which is the result of a translocation between the chromosomes 9 and 22 occurs in about 90% of CML cases.
Leukemia is categorized in subtypes which may differ regarding prognosis and the appropriate treatment modalities. Many subtypes are associated with distinct chromosomal abnormalities.
The sensitive detection of these rearrangements can be used to monitor minimal residual disease and consequently the success of an ongoing therapy.
We have established assays for the diagnosis of various chromosomal rearrangements occurring in leukemia. By identification of subtype associated translocations, prognosis or an appropriate therapy can be estimated.
Panel of translocation which can be determined at with testing:
Lymphoma Genetic Testing
Additionally, detection of minimal residual lymphoma can be done by analysis of immune-receptor rearrangements. The detection of individual, prominent VDJ-receptor rearrangements in the blood is conclusive for a clonal proliferation of lymphocytes, especially B-lymphocytes. VDJ-receptor rearrangements are found in 95 % of B-cell ALLs, but also in 14 % of T-cell ALLs.
Clonal expansion of T-cells can be diagnosed by detection of VJ-receptor rearrangements, which are found in 91 % of T-cell ALLs, but also in 55 % of B-cell ALLs.
